跳至主要内容
临床试验/ACTRN12618001977268
ACTRN12618001977268终止未知

A sub-study of an investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial (TRIDENT) to determine the effect of more intensive long-term intensive blood pressure control, provided by a fixed low-dose combination blood pressure lowering pill (Triple Pill”) strategy on top of standard of care, on chronic markers of cerebral small vessel disease in patients with a history of acute stroke due to intracerebral haemorrhage (ICH), as assessed by Magnetic Resonance Imaging (MRI).

The George Institute for Global Health0 个研究点目标入组 4 人开始时间: 2018年12月7日最近更新:
适应症

试验速览

阶段
未知
状态
终止
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Eligible for, randomised and continuing in TRIDENT Main Study
  • 2.No contraindications to MRI scan of the brain
  • 3.Provide informed consent for the MRI Sub-Study

排除标准

  • 1.Any MRI contraindications (e.g. metallic implants, claustrophobia, etc.).
  • 2.Less than 6 weeks or greater than 6 months post-randomisation (however, where possible the baseline MRI Sub-Study scan should be conducted as soon as possible after the qualifying ICH. e.g. if the qualifying ICH was 4 months prior to randomisation, the baseline scan should be done as close to 6 weeks post-randomisation as possible).

研究者

相似试验